Capital Investment Advisory Services LLC Takes $88,000 Position in Becton Dickinson and Co (BDX)

Capital Investment Advisory Services LLC bought a new position in Becton Dickinson and Co (NYSE:BDX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 390 shares of the medical instruments supplier’s stock, valued at approximately $88,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BDX. IMS Capital Management acquired a new stake in shares of Becton Dickinson and during the third quarter worth $29,000. JCIC Asset Management Inc. acquired a new stake in shares of Becton Dickinson and during the fourth quarter worth $54,000. Signet Investment Advisory Group Inc. acquired a new stake in shares of Becton Dickinson and during the fourth quarter worth $56,000. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Becton Dickinson and by 87.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 273 shares of the medical instruments supplier’s stock worth $62,000 after acquiring an additional 127 shares during the period. Finally, Essex Savings Bank acquired a new stake in shares of Becton Dickinson and during the fourth quarter worth $67,000. Institutional investors own 86.28% of the company’s stock.

In other news, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the completion of the transaction, the executive vice president now owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,243 shares of Becton Dickinson and stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $243.86, for a total transaction of $1,278,557.98. The disclosure for this sale can be found here. In the last three months, insiders sold 13,210 shares of company stock valued at $3,275,587. Insiders own 0.12% of the company’s stock.

A number of equities research analysts recently commented on the stock. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Zacks Investment Research lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. Piper Jaffray Companies lifted their price target on shares of Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research note on Tuesday, February 5th. Citigroup lowered their price target on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research note on Tuesday, November 13th. Finally, Wells Fargo & Co lowered their price target on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 7th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $253.17.

Shares of BDX stock opened at $245.05 on Thursday. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The firm has a market capitalization of $65.45 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 1.70 and a beta of 1.23.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the previous year, the business earned $2.48 EPS. The company’s revenue was up 35.1% compared to the same quarter last year. Research analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2019/02/14/capital-investment-advisory-services-llc-takes-88000-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Liquidity

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply